We aimed to evaluate its safety in the emergency neurosurgical population at a tertiary hospital center.
Introduction
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep venous thrombosis (DVT), is a well-described process that can cause significant morbidity and mortality. This is especially true in the patient population of a critical care unit [1] . The true incidence of thromboembolic disease in the critically-ill neurosurgical population admitted to a critical care setting has not been well described in the literature. In the absence of VTE thrombo-prophylaxis, the incidence of DVT has been observed between 10-40% in the general surgery population and as high as 40-60% in the major orthopedic surgery population [2] .
In addition to VTE risk, mortality rates have also been stratified with VTE prophylaxis in mind, and institution of DVT prophylaxis results in decreased mortality risk [3] [4] [5] . Multiple case reports and series on postoperative thromboembolic prophylaxis have been published, however clear guidelines for a "Best Practice" have yet to be described [6] [7] [8] . Many investigators and even whole institutions have taken to stratifying the risk for developing VTE and treating the calculated risk accordingly. Treatment modalities range from encouraging early ambulation in the hospitalized patient to the use of compression stockings and/or therapeutic medical management [9] .
Despite these ideas and methods, there is a hesitation and a paucity of data in its use the critically-ill neurosurgical population. The neurosurgery community has not developed a unified approach for the prevention of VTE thrombo-prophylaxis in this population [10] . While there is no doubt that stockings and Journal of Intensive and Critical Care ISSN 2471-8505 ambulation are effective modalities, these are of-ten not feasible options for a critically-ill neurosurgical patient. The fear behind chemoprophylaxis is the risk of causing or worsening a cerebral or spinal hemorrhage, yet these fears must be balanced with the morbidity and mortality behind DVT propagation and subsequent embolic events related to immobility.
Our institution previously published a study examining the administration of subcutaneous unfractionated heparin (SCUFH) in 522 neurosurgery patients to determine the risk of post-operative hemorrhage [11] . We found no embolic events associated with the use of SCUFH, suggesting that there was no increased risk of bleeding in the general neurosurgical population. However, in the emergency neurosurgery setting, where patients are at high risk of developing VTE, the likelihood of receiving SCUFH or other forms of prophylaxis are significantly reduced compared to non-emergency cases [12] possibly related to the potential bleeding complications. This study is a retrospective analysis of prospectively-collected data evaluating the efficacy and safety of SCUFH in patients who underwent emergency neurosurgical procedures.
Methods
This is a retrospective review of prospectively-acquired data at a single institution at Long Island Jewish Medical Center. All patients in this study were admitted to the surgical intensive care unit and cared for by a dedicated surgical critical care team. We documented whether patients subcutaneous unfractionated heparin or not for venous thromboembolism (VTE) prophylaxis. Stratification of SCUFH was based upon the admitting and/or operating attending preference after discussion with the SICU attending. Of the patients receiving SCUFH, we delineated if patients received SCUFH within 24 h of surgery or greater than 24 h after surgery. All SCUFH patients received 5000 units of SCUFH every eight h until discharge, and no study patients were stopped prematurely or changed to low-molecular weight heparin (LMWH) products. All patients routinely received lower extremity compression boots; compliance was monitored by the nursing staff as per hospital policy. The patients were followed until date of discharge from SICU or death.
Inclusion criteria consisted of all neurosurgical and head trauma patients who required surgical intervention in the emergency setting. None of these patients had a history of heparin induced thrombocytopenia (HIT), PE or DVT. General patient characteristics were collected, including but not limited to: Age, gender, height, weight, body mass index and the amount of day under mechanical ventilation. Other factors taken into consideration included patient condition on admission to the intensive care unit; the ICU length of stay (LOS); units of blood transfused; ICU severity score including the Acute Physiology and Chronic Health Evaluation (APACHE) II score [13, 14] , APACHE III [13, 15] , Simplified Acute Physiology Score (SAPS) [16] , Multiple Organ Dysfunction score (MODS) [17] ; survival outcomes; and complications (heparin induced thrombocytopenia [HIT], deep vein thrombosis [18] , and pulmonary embolism [PE], postoperative bleeding, and vasospasm). Postoperative bleeding, PE and vasospasm were evaluated clinically and/or with computed axial tomographic scan (CT scan). Studies were only ordered after a neurosurgical evaluation was performed and if there was a high index of suspicion for intracranial bleeding or an acute change in mental status. As per institution policy, DVT screening ultrasounds were not routinely performed, and evaluation of DVT was performed in setting of high clinical suspicion. Data was compiled, reviewed, and verified for accuracy by multiple independent reviewers.
Associations between categorical factors were examined using the chi-square test or Fisher's exact test, or Pearson correlation coefficients. Associations between continuous factors (BMI, Age, APACHE score, APACHE III score, SAPS, MODS) were examined using the Mann-Whitney U test. LOS in the SICU was calculated using the product-limit method. Mortality was described using the Kaplan-Meier method. For all study measures, a p-value <0.05 indicated statistical significance. Data was collected and subsequently submitted to the biostatistics department for analysis. This study was approved by the Northwell Health System Institutional Review Board.
Results
We Table 1 . We found no statistically significant differences in age, ethnicity, sex, and patient condition upon discharge from SICU between the patients who did not receive heparin, those who received SCUFH within 24 h, and those who received SCUFH after 24 h. 
Discussion
This study aimed to evaluate the efficacy and safety of SCUFH in high-risk neurosurgical patients undergoing emergency surgery. We recently found that the use of SCUFH in the general neurosurgical population was safe, however, the potential adverse effects of SCUFH in the high-risk neurosurgery patients undergoing emergency surgery was largely unknown.
By collecting data on 1,152 patients-days at a single center, this large retrospective study identified several correlations between the patient demographics and perioperative characteristics with the risk of developing bleeding complications.
This trend may be related to the increased comorbidities and longer LOS seen in the heparin group, as these patients were Table 3 Admitting diagnoses/procedures of critically ill neurological patients.
(): Values are represented in percentage. SCUFH: Subcutaneous Unfractionated Heparin; *: Statistically Significant selected to receive SCUFH whereas the less complex patients did not. Meyer curve (Figure 1 ) demonstrated a significant p value when comparing no SCUFH to either arm of the heparin group. Since the non-heparin group had the worst survival and the heparin groups both had improved outcomes it could be inferred that the heparin improved survival. However, clinically is not significant as the data may be confounded. Patients may have been sicker or transfers from the SICU to the floor delayed. While our cohort was not randomized into the different treatment regimens, Table 1 shows that these groups were well matched.
Evaluation of the data and the Kaplan
Significant statistical association was noted with the multiple organ dysfunction score ( 
Journal of Intensive and Critical Care ISSN 2471-8505
well as quantify subsequent deterioration over the course of the ICU stay [17] . The MODS was constructed using simple measures of dysfunction in six organ systems and, therefore, may not be applicable to the emergency neurosurgical post-operative population.
We hypothesized that a number of other variables may affect the likelihood of post-operative VTE, including BMI, advanced age, anticoagulation medication (Table 1 ) and admitting diagnoses and procedures (Table 3 ). However, none of these hypotheses were statistically significant. It is possible that this study may be underpowered to detect these differences.
Abundant data from other meta-analyses and placebo-controlled, blinded, randomized clinical trials have demonstrated the overall safety of anticoagulation, as the marginally increased rates of bleeding with prophylactic doses of low-dose unfractionated heparin (LDUH), low molecular weight heparin (LMWH), or a vitamin K antagonist (VKA) are not of clinical significance [19, 20] . Several studies support the usage in the neurosurgical population as well [21] [22] [23] [24] . The belief that pharmacologic VTE prophylaxis should be withheld in any patient at increased risk for bleeding is largely unsupported by literature, it is yet a practice widely performed.
Prospective studies of neurosurgical patients who received perioperative LDUH prophylaxis, has not shown increased risk of intracranial bleeding. Studies show that perioperative administration of heparin does not significantly alter bleeding tendency by any measured parameter [25] [26] [27] [28] [29] [30] . This analysis confirms previous conclusions and supports the usage of subcutaneous heparin, even in emergency neurosurgical patients. It is clear that the administration of SCUFH does not 
SCUFH: Subcutaneous Unfractionated Heparin; ICU:
Intensive Care Unit directly cause postoperative hemorrhage. Our findings support the above claims that the administration of subcutaneous heparin in the postoperative period is safe, even in patients with SAH.
Our Study has some limitations. First, although data were prospectively entered into the eICU database, our evaluation was retrospective. Thus, vulnerable to residual cofounding which could have explained the lack of association between both SCUFH groups and mortality. However, those uncaptured factors would need to have an overwhelming effect in order to hide that association, which we believe is highly unlikely. Second, given the lack of post-operative VTE or bleeding events we observed in Table 4 , our study may not have sufficient power to show a significance association. Our failure to enroll and analyse a larger number of patients could have led to a type-II error. Because of limitations in our dataset, we were not able to measure the median time to the Operating Room since admission. Information that could have been helpful to better support the emergency nature from our cohort. Nonetheless, our cohort includes only the patients who receive neurosurgical intervention within the first 24 h post-admission. Finally, it should be noted that the years from 2008 to 2010 reflect a period of changing practice as regards corticosteroid usage in septic shock
In spite of this limitation, our findings highlight the importance of the on-going controversies and discussions about the use of SCUFH in neurosurgical patients after emergency procedures.
In addition, to our knowledge, this study is one of the largest single center studies on bleeding complications in emergency neurosurgical patients.
Conclusion
Based on the above analysis, the administration of SCUFH in emergency neurosurgical patient at 24 h, dosed accordingly to guidelines for thromboembolism, does not appear to be associated with increase post operatively bleeding and continues to be a safe and effective chemoprophylaxis against DVT. Our study suggests that for post-operative bleeding neurosurgical patients, the administration of SCUFH should be routinely used as a VTE prophylactic agent and that it is not an independent risk factor. Further studies are warranted in a controlled, multicenter, randomized way to confirm the safety and effectiveness use of SCUFH in the treatment and prevention against DVT.
